Information Provided By: 
Fly News Breaks for January 24, 2020
AYX
Jan 24, 2020 | 07:33 EDT
Wedbush analyst Steve Koenig raised his price target for Alteryx to $152 from $126 and maintained an Outperform rating. Koenig tells investors in a research note that while strong year-to-date share price performance creates a more challenging set-up headed into the Q4 print, he continues to like the risk/reward profile over the next 12 months. The analyst adds that he is "relatively confident" there will be strong outperformance on EPS, revenue and other major metrics.
News For AYX From the Last 2 Days
AYX
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
